HOTAIRM1 and central nervous system cancer: Conversely, increased expression of HOTAIRM1 was relevant to the limited clinical efficacy of temozolomide (TMZ) treatment, while knocking down HOTAIRM1 resulted in a lower IC50 in two glioma cell lines for TMZ.